Summary & Overview
HCPCS J9380: Injection, teclistamab-cqyv, 0.5 mg
HCPCS Level II code J9380 represents the injectable biologic teclistamab-cqyv, billed per 0.5 mg unit. As a recently introduced monoclonal antibody therapy administered by injection, this code captures the drug product used in outpatient infusion centers and ambulatory oncology clinics. Nationally, accurate coding of such high-cost specialty biologics is critical for claims processing, patient access, and payer coverage decisions.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the payers commonly involved in coverage decisions for specialty injectable therapies. The publication outlines benchmarking elements and policy considerations relevant to hospital and clinic billing teams, pharmacy benefit managers, and reimbursement analysts.
This report highlights what providers and billing professionals need to know about HCPCS Level II code J9380: the clinical setting for administration, how the code is used to represent the drug product on claims, and where to look for payer-specific coverage and reimbursement information. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9380 describes the injection of teclistamab-cqyv, packaged as 0.5 mg per billing unit. The service represented is administration of a prescription biologic (teclistamab-cqyv) intended for parenteral injection.
Service type: Injectable biologic therapy (monoclonal antibody)
Typical site of service: Outpatient infusion or ambulatory oncology clinic, where patients receive parenteral biologic treatments.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old with relapsed or refractory multiple myeloma who has exhausted standard lines of therapy and is being treated with teclistamab-cqyv as a bispecific T-cell engager given by subcutaneous or intravenous injection per product labeling. The clinical workflow begins with eligibility confirmation (disease progression, prior therapies, performance status), baseline laboratory assessment (CBC, metabolic panel, liver and renal function), infectious disease screening and vaccination review, and informed consent. On treatment day, nursing performs pre-medication (antipyretic, antihistamine, corticosteroid as indicated), verifies the prescribed dose in mg and converts to required vial units of J9380 (each unit = 0.5 mg), obtains baseline vital signs and oxygen saturation, and documents infusion/injection start and stop times. Post-administration monitoring includes vital signs and observation for cytokine release syndrome or immune effector cell-associated neurotoxicity, with empiric management protocols available. Documentation includes drug name teclistamab-cqyv, dosage administered, number of J9380 units billed, lot number, route of administration, administration site, and any applicable modifier(s). Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on patient coverage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|